Infectious Agent

Infection is caused by gram-negative, spiral-shaped microaerophilic bacteria of the family Campylobacteriaceae. Most infections are caused by Campylobacter jejuni ; at least 18 other species, including C. coli , also cause infection. C. jejuni and C. coli are carried normally in the intestinal tracts of many domestic and wild animals.


The major modes of transmission include eating contaminated foods (especially undercooked chicken and foods contaminated by raw chicken), drinking contaminated water or milk (unpasteurized milk, most commonly), and having contact with animals, particularly farm animals such as cows and chickens, as well as domestic cats and dogs. Campylobacter can also be transmitted from person to person by the fecal-oral route.


Campylobacter is a leading cause of bacterial diarrheal disease worldwide; in the United States, it is estimated to cause 1.3 million human illnesses every year. Campylobacter is the most common laboratory-confirmed enteric pathogen reported in travelers returning to the United States from every region of the world. The risk of infection is highest in travelers to Africa and South America, especially in areas with poor restaurant hygiene and inadequate sanitation. The infectious dose is small; <500 organisms can cause disease.

Clinical Presentation

Incubation period is typically 2–4 days. Campylobacteriosis is characterized by diarrhea (frequently bloody), abdominal pain, fever, and occasionally nausea and vomiting. More severe illness can occur, including dehydration, bloodstream infection, and symptoms mimicking acute appendicitis or ulcerative colitis. People with campylobacteriosis are at increased risk for postinfectious complications, including reactive arthritis (2%–5% of patients), irritable bowel syndrome (9%–13%), and Guillain-Barré syndrome (GBS) (0.1%). C. jejuni is the most frequently observed antecedent bacterial infection in cases of GBS; symptoms usually begin 1–3 weeks after the onset of Campylobacter enteritis.


Diagnosis is traditionally based on isolation of the organism from stool specimens or rectal swabs by using selective media incubated under reduced oxygen tension at 42°C (107.6°F) for 72 hours. Visualization of motile and curved, spiral, or S-shaped rods by stool phase-contrast or dark-field microscopy can provide rapid presumptive evidence for Campylobacter enteritis. A stool specimen should be collected during the acute phase of the diarrheal illness and before antibiotic treatment is initiated. Because the organism is fastidious, a delay in transporting the specimen will affect the viability of Campylobacter spp. A laboratory may reject stool samples without preservative that are in transit for more than 2 hours. If transport and processing are not possible within 2 hours of stool sample collection, specimens should be placed in transport medium according to standard guidelines. Only through culture can Campylobacter be subtyped and tested for antimicrobial susceptibility. Rapid culture-independent diagnostic tests, including both antigen tests and nucleic acid–based tests, are becoming widely available and more commonly used. The sensitivity and specificity of stool antigen tests are variable, and in settings of low prevalence, the positive predictive value is likely to be low. Therefore, laboratories should confirm positive results of stool antigen tests by culture. Nucleic acid–based tests have recently been approved and appear to have higher sensitivity and specificity than the antigen tests. Campylobacteriosis is a nationally notifiable disease.


The disease is generally self-limited, lasting a week or less. Antibiotic therapy decreases the duration of symptoms and bacterial shedding if administered early in the course of disease. Because campylobacteriosis generally cannot be distinguished from other causes of travelers’ diarrhea without a diagnostic test, the use of empiric antibiotics in travelers should follow the guidelines for travelers’ diarrhea.

Rates of antibiotic resistance, especially fluoroquinolone resistance, have risen sharply in the past 20 years, and high rates of resistance are now seen in many regions. Travel abroad is a risk factor for infection with resistant Campylobacter . Clinicians should suspect resistant infection in returning travelers with campylobacteriosis in whom empiric fluoroquinolone treatment has failed. When fluoroquinolone resistance is proven or suspected, azithromycin is usually the next choice of treatment, although resistance to macrolides has also been reported.


No vaccine is available. Prevention is best achieved by adhering to standard food and water safety precautions (see Chapter 2, Food & Water Precautions) and thorough handwashing after contact with animals or environments that may be contaminated with animal feces. Antibiotic prophylaxis is not recommended.

CDC website:


  1. Coker AO, Isokpehi RD, Thomas BN, Amisu KO, Obi CL. Human campylobacteriosis in developing countries. Emerg Infect Dis. 2002 Mar;8(3):237–44.  [PMID:11927019]
  2. Fitzgerald C, Nachamkin I.Campylobacter and Arcobacter . In: Jorgensen JH, Pfaller MA, Carroll KC, Funke G, Landry ML, Richter SS, et al., editors. Manual of Clinical Microbiology. 11th ed. Washington, D. C.: American Society for Microbiology Press; 2015. pp. 998–1012.
  3. Friedman CR, Hoekstra RM, Samuel M, Marcus R, Bender J, Shiferaw B, et al. Risk factors for sporadic Campylobacter infection in the United States: a case-control study in FoodNet sites. Clin Infect Dis. 2004 Apr 15;38 Suppl 3:S285–96.  [PMID:15095201]
  4. Humphrey T, O'Brien S, Madsen M. Campylobacters as zoonotic pathogens: a food production perspective. Int J Food Microbiol. 2007 Jul 15;117(3):237–57.  [PMID:17368847]
  5. Kassenborg HD, Smith KE, Vugia DJ, Rabatsky-Ehr T, Bates MR, Carter MA, et al. Fluoroquinolone-resistant Campylobacter infections: eating poultry outside of the home and foreign travel are risk factors. Clin Infect Dis. 2004 Apr 15;38 Suppl 3:S279–84.  [PMID:15095200]
  6. Kendall ME, Crim S, Fullerton K, Han PV, Cronquist AB, Shiferaw B, et al. Travel-associated enteric infections diagnosed after return to the United States, Foodborne Diseases Active Surveillance Network (FoodNet), 2004–2009. Clin Infect Dis. 2012 Jun;54 Suppl 5:S480–7.  [PMID:22572673]
  7. Moore JE, Barton MD, Blair IS, Corcoran D, Dooley JS, Fanning S, et al. The epidemiology of antibiotic resistance in Campylobacter . Microbes Infect. 2006 Jun;8(7):1955–66.  [PMID:16716632]
  8. World Health Organization. The global view of campylobacteriosis: report of an expert consultation. Geneva: World Health Organization; 2012 [cited 2016 Sep. 21]. Available from:
  9. World Health Organization. WHO estimates of the global burden of foodborne diseases. Geneva: World Health Organization; 2015 [cited 2016 Sep. 22]. Available from:


Aimee L. Geissler, Barbara E. Mahon, Collette Fitzgerald